Express Scripts Officials Offer Value-Based Migraine Program

Once on preventive therapy, these neuroscience specialist pharmacists will offer coaching for members to achieve optimal medication adherence, and to help members avoid migraine triggers.

Officials with Express Scripts this week announced a value-based migraine program, SafeGuardRx SM Migraine Care ValueSM, set to begin April 1, 2019.

According to a prepared statement from Express Scripts, this "industry-first program combines a comprehensive clinical care program to help patients achieve better outcomes and experience fewer migraines, while helping plan sponsors more affordably cover new, preventive therapy for their members."

The goal of the program is to revent migraines from "coming on at all," Harold Carter, PharmD, Senior Director, Product, Express Scripts, explained in the statement. "Through the clinical care provided through our new Migraine Care Value program, Express Scripts specialist pharmacists in our Neuroscience Therapeutic Resource Center will identify patients using high amounts of acute migraine treatments, and work with them and their physician to move them to an appropriate preventive treatment."

Once on preventive therapy, these neuroscience specialist pharmacists will offer coaching for members to achieve optimal medication adherence, and to help members avoid migraine triggers. For members using newer calcitonin gene-related peptide (CGRP) inhibitors, Express Scripts pharmacists will coach them on how to use these injectable medications and overcome barriers to achieving optimal results. Clinical evidence for recently approved CGRP inhibitors has shown these therapies are effective in reducing the frequency of migraine headaches in patients who experience 4 or more migraines per month. While drug makers have priced CRGP inhibitors in line with independent value-based assessments from organizations such as the Institute for Clinical and Economic Review (ICER), they are significantly more costly than previously available preventive migraine therapies and thus require conscientious management to ensure optimal patient outcomes, according to information contained in the statement.

Not all patients with migraines require CGRP-inhibitor therapy, but for those patients who meet the clinical guidelines for CGRP therapy, the Migraine Care Value program will prefer erenumab-aooe (Aimovig) and galcanezumab-gnlm (Emgality). As with any new-to-market medication, some patients will feel CGRP-inhibitors do not work for them. To help minimize plan sponsor exposure to the high cost of these therapies, Express Scripts is offering an early discontinuation reimbursement back to the plan sponsor when a patient discontinues therapy in the first 90 days.

"CGRP inhibitors can be life-changing for people with frequent migraines which is why it's critical that these drugs be made affordable to both patients and plan sponsors," said Carter. "With our SafeGuardRx solutions, we have pioneered an evidence-based approach that will now help migraine sufferers receive the best medication and specialized care to enable them to lead full and productive lives while reducing costs and wasteful spending for our clients."

Reference

1. Express Scripts Offers New Value-Based Program for Migraine [news release]. St. Louis. Express Scripts website. Oct. 17, 2018. https://expressscriptsholdingco.gcs-web.com/news-releases/news-release-details/express-scripts-offers-new-value-based-program-migraine